Online Liquid Biopsy Analysis

The Liquid Biopsy ONLINE series, a 3-part event, is set to delve into the latest advancements and challenges in the clinical use of liquid biopsies for precision oncology. The series, scheduled to kick off on Tuesday 14 November at 3pm GMT / 4pm CET / 10am EST, will feature experts in the field discussing applications, challenges, and benefits of liquid biopsies.

In the first webinar, attendees can expect a focus on leveraging liquid biopsies for a more personalized approach to cancer treatment and monitoring. The session will be presented by an esteemed speaker, whose identity has yet to be revealed.

Moving forward, the second webinar, scheduled for Tuesday 21 November at the same time, will delve into liquid biopsy for MRD and resistance detection. Talk 1, titled "Monitoring MRD in Colorectal Cancer to Advance Precision Medicine," will be presented by Pashtoon Kasi. Another highlight of the second webinar is Talk 2, titled "Advancing MRD Detection in Patients with Hematologic Cancers," presented by David Kurtz.

The third webinar, scheduled for Tuesday 28 November, will focus on overcoming challenges and establishing the clinical utility of liquid biopsies. Key discussions will include the latest methods and innovations improving the sensitivity, reliability, and clinical utility of liquid biopsies. Talk 3, titled "Plasma-first Approach for Molecular Genotyping in Non-small Cell Lung Cancer: opportunities and challenges," will be presented by Miguel García-Pardo. Moreover, Talk 2, titled "Clinical Considerations for the Implementation of Liquid Biopsy Testing in Lung Cancer Patients," will be presented by Paul Hofman. The third webinar will culminate with Talk 1, titled "Injectable Priming Agents and Sequencing Technology Innovations to Improve Liquid Biopsy Testing," presented by Viktor Adalsteinsson.

The series will also address considerations regarding the clinical use of liquid biopsies. Attendees will gain insights into the latest biomarkers and assays for MRD detection, as well as the latest liquid biopsy assays for various biomarkers and tumor types.

Registration for one webinar in the series grants access to all subsequent webinars in the series. Joining the second webinar will provide insights into the latest biomarkers and assays for MRD detection, while attending Liquid Biopsy ONLINE will offer a comprehensive understanding of the latest advancements and challenges in the field.

[1] American Cancer Society. (2020). Circulating tumor DNA (ctDNA) testing. Retrieved from https://www.cancer.org/treatment/understanding-your-diagnosis/genetic-changes/circulating-tumor-dna-ctdna-testing.html [2] National Cancer Institute. (2020). Liquid biopsy. Retrieved from https://www.cancer.gov/publications/dictionaries/cancer-terms/def/liquid-biopsy [3] D'Souza, G., & Kwong, A. (2020). Liquid biopsy for the detection of minimal residual disease in cancer. Nature Reviews Clinical Oncology, 17(1), 3-12. [4] National Comprehensive Cancer Network. (2020). Liquid biopsy guidelines. Retrieved from https://www.nccn.org/professionals/physician_gls/f_guidelines.asp?f=151

The Liquid Biopsy ONLINE series explores the latest advancements and challenges in the clinical use of liquid biopsies for precision oncology.
In the first webinar, attendees can learn about using liquid biopsies for a more personalized approach to cancer treatment and monitoring.
The second webinar discussing liquid biopsy for MRD and resistance detection will feature talks on monitoring MRD in Colorectal Cancer and advancing MRD detection in patients with Hematologic Cancers.
The third webinar will focus on overcoming challenges and establishing the clinical utility of liquid biopsies, including discussions on the latest methods and innovations.
Access to the latest biomarkers and assays for MRD detection will be discussed in the second webinar, while a comprehensive understanding of the field's latest advancements and challenges will be offered through attending the entire series.
Liquid biopsies involve the analysis of DNA found in circulating tumor cells, blood, or other bodily fluids to help in the diagnosis, monitoring, and treatment of different medical-conditions, such as cancer.
Circulating tumor DNA (ctDNA) testing is a diagnostic tool that uses liquid biopsy to detect DNA fragments in the blood, which can be indicative of the presence of cancer or the spread of cancer cells.
Liquid biopsy guidelines from organizations such as the National Comprehensive Cancer Network and the American Cancer Society provide clinical information and recommendations for the use of liquid biopsies in various health-and-wellness contexts, including therapies-and-treatments for cancer.